Ashfield Capital Partners LLC reduced its stake in shares of Amgen, Inc. (NASDAQ:AMGN) by 1.9% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 56,782 shares of the medical research company’s stock after selling 1,105 shares during the period. Amgen makes up approximately 1.3% of Ashfield Capital Partners LLC’s investment portfolio, making the stock its 20th biggest holding. Ashfield Capital Partners LLC’s holdings in Amgen were worth $11,770,000 at the end of the most recent reporting period.
Several other large investors also recently bought and sold shares of the company. LSV Asset Management lifted its position in Amgen by 3.2% during the second quarter. LSV Asset Management now owns 4,157,649 shares of the medical research company’s stock valued at $767,460,000 after purchasing an additional 128,865 shares during the period. Schwab Charles Investment Management Inc. lifted its position in Amgen by 2.3% during the second quarter. Schwab Charles Investment Management Inc. now owns 3,207,242 shares of the medical research company’s stock valued at $592,025,000 after purchasing an additional 72,205 shares during the period. Dimensional Fund Advisors LP lifted its position in Amgen by 17.0% during the second quarter. Dimensional Fund Advisors LP now owns 2,365,045 shares of the medical research company’s stock valued at $436,551,000 after purchasing an additional 343,690 shares during the period. Bank of Montreal Can lifted its position in Amgen by 13.4% during the third quarter. Bank of Montreal Can now owns 2,328,857 shares of the medical research company’s stock valued at $482,749,000 after purchasing an additional 275,469 shares during the period. Finally, Swiss National Bank lifted its position in Amgen by 3.2% during the second quarter. Swiss National Bank now owns 2,227,926 shares of the medical research company’s stock valued at $411,253,000 after purchasing an additional 69,500 shares during the period. Institutional investors and hedge funds own 82.37% of the company’s stock.
AMGN opened at $193.16 on Friday. Amgen, Inc. has a fifty-two week low of $163.31 and a fifty-two week high of $210.19. The company has a debt-to-equity ratio of 2.05, a current ratio of 3.08 and a quick ratio of 2.84. The firm has a market capitalization of $121.55 billion, a price-to-earnings ratio of 15.35, a PEG ratio of 1.98 and a beta of 1.37.
Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, October 30th. The medical research company reported $3.69 earnings per share for the quarter, beating analysts’ consensus estimates of $3.45 by $0.24. Amgen had a net margin of 9.44% and a return on equity of 54.14%. The company had revenue of $5.90 billion during the quarter, compared to analysts’ expectations of $5.78 billion. During the same quarter in the previous year, the company earned $3.27 earnings per share. The firm’s revenue for the quarter was up 2.3% on a year-over-year basis. As a group, equities analysts anticipate that Amgen, Inc. will post 14.24 EPS for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 7th. Shareholders of record on Friday, November 16th will be issued a $1.32 dividend. The ex-dividend date of this dividend is Thursday, November 15th. This represents a $5.28 dividend on an annualized basis and a yield of 2.73%. Amgen’s payout ratio is 41.97%.
A number of research analysts recently issued reports on AMGN shares. Cann restated a “buy” rating and set a $224.00 target price on shares of Amgen in a research report on Monday, July 30th. Oppenheimer restated a “buy” rating and set a $224.00 target price on shares of Amgen in a research report on Monday, July 30th. Mizuho restated a “buy” rating and set a $200.00 target price on shares of Amgen in a research report on Friday, July 27th. Goldman Sachs Group restated a “buy” rating and set a $228.00 target price on shares of Amgen in a research report on Friday, July 27th. Finally, Royal Bank of Canada set a $193.00 target price on shares of Amgen and gave the company a “buy” rating in a research report on Friday, July 27th. One research analyst has rated the stock with a sell rating, thirteen have issued a hold rating and eleven have assigned a buy rating to the company. Amgen currently has an average rating of “Hold” and a consensus target price of $204.55.
TRADEMARK VIOLATION WARNING: This piece was posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this piece can be read at https://www.americanbankingnews.com/2018/11/10/ashfield-capital-partners-llc-lowers-stake-in-amgen-inc-amgn.html.
Amgen Company Profile
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.
Recommended Story: Fundamental Analysis – How It Helps Investors
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.